|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: ATP10B |
Gene summary for ATP10B |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | ATP10B | Gene ID | 23120 |
| Gene name | ATPase phospholipid transporting 10B (putative) | |
| Gene Alias | ATPVB | |
| Cytomap | 5q34 | |
| Gene Type | protein-coding | GO ID | GO:0006810 | UniProtAcc | O94823 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 23120 | ATP10B | HTA11_3410_2000001011 | Human | Colorectum | AD | 6.13e-45 | -9.93e-01 | 0.0155 |
| 23120 | ATP10B | HTA11_2487_2000001011 | Human | Colorectum | SER | 2.75e-10 | -6.87e-01 | -0.1808 |
| 23120 | ATP10B | HTA11_2951_2000001011 | Human | Colorectum | AD | 1.44e-04 | -9.01e-01 | 0.0216 |
| 23120 | ATP10B | HTA11_347_2000001011 | Human | Colorectum | AD | 2.14e-06 | 5.12e-01 | -0.1954 |
| 23120 | ATP10B | HTA11_2112_2000001011 | Human | Colorectum | SER | 2.67e-02 | -7.33e-01 | -0.2196 |
| 23120 | ATP10B | HTA11_3361_2000001011 | Human | Colorectum | AD | 1.81e-20 | -9.45e-01 | -0.1207 |
| 23120 | ATP10B | HTA11_696_2000001011 | Human | Colorectum | AD | 2.00e-20 | -6.28e-01 | -0.1464 |
| 23120 | ATP10B | HTA11_5216_2000001011 | Human | Colorectum | SER | 3.24e-06 | -5.74e-01 | -0.1462 |
| 23120 | ATP10B | HTA11_546_2000001011 | Human | Colorectum | AD | 7.93e-04 | -5.12e-01 | -0.0842 |
| 23120 | ATP10B | HTA11_9341_2000001011 | Human | Colorectum | SER | 2.18e-03 | -9.53e-01 | -0.00410000000000005 |
| 23120 | ATP10B | HTA11_866_3004761011 | Human | Colorectum | AD | 1.93e-09 | -5.64e-01 | 0.096 |
| 23120 | ATP10B | HTA11_4255_2000001011 | Human | Colorectum | SER | 1.06e-02 | -7.61e-01 | 0.0446 |
| 23120 | ATP10B | HTA11_9408_2000001011 | Human | Colorectum | AD | 3.09e-08 | -1.09e+00 | 0.0451 |
| 23120 | ATP10B | HTA11_8622_2000001021 | Human | Colorectum | SER | 1.01e-12 | -9.89e-01 | 0.0528 |
| 23120 | ATP10B | HTA11_10711_2000001011 | Human | Colorectum | AD | 2.37e-19 | -9.00e-01 | 0.0338 |
| 23120 | ATP10B | HTA11_7696_3000711011 | Human | Colorectum | AD | 7.57e-26 | -6.44e-01 | 0.0674 |
| 23120 | ATP10B | HTA11_6818_2000001011 | Human | Colorectum | AD | 4.82e-10 | -7.30e-01 | 0.0112 |
| 23120 | ATP10B | HTA11_11156_2000001011 | Human | Colorectum | AD | 2.71e-05 | -1.16e+00 | 0.0397 |
| 23120 | ATP10B | HTA11_6818_2000001021 | Human | Colorectum | AD | 2.64e-02 | -4.27e-01 | 0.0588 |
| 23120 | ATP10B | HTA11_99999970781_79442 | Human | Colorectum | MSS | 9.65e-06 | -3.61e-01 | 0.294 |
| Page: 1 2 3 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer | ||
| Lung |  | AAH: Atypical adenomatous hyperplasia |
| AIS: Adenocarcinoma in situ | ||
| IAC: Invasive lung adenocarcinoma | ||
| MIA: Minimally invasive adenocarcinoma |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:0010876 | Colorectum | AD | lipid localization | 120/3918 | 448/18723 | 1.59e-03 | 1.33e-02 | 120 |
| GO:0006869 | Colorectum | AD | lipid transport | 108/3918 | 398/18723 | 1.67e-03 | 1.39e-02 | 108 |
| GO:0007033 | Colorectum | AD | vacuole organization | 53/3918 | 180/18723 | 4.18e-03 | 2.89e-02 | 53 |
| GO:0015748 | Colorectum | AD | organophosphate ester transport | 42/3918 | 140/18723 | 7.04e-03 | 4.31e-02 | 42 |
| GO:00070331 | Colorectum | MSS | vacuole organization | 48/3467 | 180/18723 | 4.32e-03 | 3.07e-02 | 48 |
| GO:00108761 | Colorectum | MSS | lipid localization | 104/3467 | 448/18723 | 6.76e-03 | 4.38e-02 | 104 |
| GO:00068691 | Colorectum | FAP | lipid transport | 81/2622 | 398/18723 | 2.84e-04 | 3.76e-03 | 81 |
| GO:00108762 | Colorectum | FAP | lipid localization | 85/2622 | 448/18723 | 1.92e-03 | 1.63e-02 | 85 |
| GO:0015914 | Colorectum | FAP | phospholipid transport | 23/2622 | 96/18723 | 6.09e-03 | 3.82e-02 | 23 |
| GO:00068692 | Colorectum | CRC | lipid transport | 63/2078 | 398/18723 | 2.36e-03 | 2.26e-02 | 63 |
| GO:00108763 | Colorectum | CRC | lipid localization | 68/2078 | 448/18723 | 4.60e-03 | 3.58e-02 | 68 |
| GO:00159142 | Lung | IAC | phospholipid transport | 20/2061 | 96/18723 | 3.58e-03 | 3.00e-02 | 20 |
| GO:00157482 | Lung | IAC | organophosphate ester transport | 26/2061 | 140/18723 | 5.22e-03 | 3.97e-02 | 26 |
| GO:001591411 | Lung | AIS | phospholipid transport | 18/1849 | 96/18723 | 5.64e-03 | 4.76e-02 | 18 |
| GO:00070333 | Lung | AIS | vacuole organization | 29/1849 | 180/18723 | 5.70e-03 | 4.80e-02 | 29 |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| ATP10B | SNV | Missense_Mutation | c.874N>C | p.Glu292Gln | p.E292Q | O94823 | protein_coding | deleterious(0) | possibly_damaging(0.864) | TCGA-A2-A04W-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | SD | |
| ATP10B | SNV | Missense_Mutation | c.1057N>T | p.Ala353Ser | p.A353S | O94823 | protein_coding | tolerated(0.65) | benign(0.015) | TCGA-A7-A0DA-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD | |
| ATP10B | SNV | Missense_Mutation | novel | c.298N>A | p.Phe100Ile | p.F100I | O94823 | protein_coding | deleterious(0.05) | benign(0.035) | TCGA-A8-A06X-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| ATP10B | SNV | Missense_Mutation | c.77N>C | p.Glu26Ala | p.E26A | O94823 | protein_coding | deleterious(0.05) | possibly_damaging(0.787) | TCGA-A8-A09I-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | anastrozole | SD | |
| ATP10B | SNV | Missense_Mutation | c.136N>T | p.Arg46Trp | p.R46W | O94823 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-A8-A09Z-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| ATP10B | SNV | Missense_Mutation | rs761267388 | c.1297N>A | p.Asp433Asn | p.D433N | O94823 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-AC-A5XS-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | femara | SD |
| ATP10B | SNV | Missense_Mutation | c.2212N>A | p.Leu738Ile | p.L738I | O94823 | protein_coding | deleterious(0) | probably_damaging(0.912) | TCGA-AO-A0J5-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Other, specify in notesBisphosphonate | zoledronic | PD | |
| ATP10B | SNV | Missense_Mutation | rs369273403 | c.931C>T | p.Arg311Trp | p.R311W | O94823 | protein_coding | deleterious(0) | probably_damaging(0.966) | TCGA-BH-A18G-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| ATP10B | SNV | Missense_Mutation | c.2299N>C | p.Asp767His | p.D767H | O94823 | protein_coding | deleterious(0.02) | probably_damaging(1) | TCGA-BH-A18K-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | PD | |
| ATP10B | SNV | Missense_Mutation | rs745441912 | c.1588T>C | p.Ser530Pro | p.S530P | O94823 | protein_coding | tolerated(0.18) | possibly_damaging(0.522) | TCGA-C8-A12X-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |